VivoSeq
Other

Proctosigmoiditis

3

Pipeline Programs↗

0

Active Trials↗

3

Companies Involved↗

Proctosigmoiditis is an early-stage landscape with 3 programs across 3 companies. The most active players are Bayer, Salix, Entero Therapeutics. 1 program is in Phase 3.

Intelligence

Pipeline Metrics

Competitive Density

21/100

Pipeline Velocity

0/100

Mech. Concentration

100/100

Completion Rate

60/100

Attrition Rate

40/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

Bayer logo

Bayer

1 program

Phase 2S

Salix

1 program

Phase 3E

Entero Therapeutics

0 programs

Preclinical

Pipeline

Programs by Phase

Analysis

Trial Status

5

clinical trials

Completed3 · 60%
Terminated2 · 40%

Clinical Trials

Trial Activity

Efficacy and Safety of Budesonide Foam for Participants With Active Mild to Moderate Ulcerative Proctitis or Proctosigmoiditis
Completed·BBausch Health Americas, Inc.·Phase 3·NCT01008410·265 enrolled
Efficacy and Safety of Budesonide Foam for Participants With Active Mild to Moderate Ulcerative Proctitis or Proctosigmoiditis
Completed·BBausch Health Americas, Inc.·Phase 3·NCT01008423·281 enrolled
The Safety and Tolerability of Budesonide Foam in Participants With Active Ulcerative Proctitis or Proctosigmoiditis
Terminated·BBausch Health Americas, Inc.·Phase 3·NCT01349673·114 enrolled
RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL OF ENEMA ALOE VERA GEL IN ACTIVE ULCERATIVE PROCTOSIGMOIDITIS.
Completed·OOspedale Sandro Pertini, Roma·N/A·NCT04753775·44 enrolled
A Study of Niclosamide Enemas in Subjects With Active Ulcerative Proctitis or Ulcerative Proctosigmoiditis
Terminated·EEntero Therapeutics·Phase 1/2·NCT03521232·27 enrolled

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)